Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | OGT | O15294 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 3/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971390 | 0.87 | F11 (0.34) | KMO | |
| Bromide SCHEMBL16971966 | 0.85 | F11 (0.35) | KMO | |
| SCHEMBL16971605 | 0.84 | NOTUM (0.44) | BCHEKMO | |
| SCHEMBL16972063 | 0.82 | AR (0.38) | — | |
| SCHEMBL16971676 | 0.82 | NOTUM (0.37) | — | |
| SCHEMBL16971553 | 0.81 | NOTUM (0.42) | KMO | |
| SCHEMBL16971531 | 0.81 | GABRA2 (0.38) | CA1CA2CA9CA12MIF | |
| SCHEMBL30271779 | 0.81 | NOTUM (0.42) | KMO | |
| SCHEMBL16972185 | 0.79 | RXRA (0.33) | — | |
| Bromide SCHEMBL16974661 | 0.78 | RXRA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-20 | — | — | US | disclosed |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3392249-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
| EP-3099687-B1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-22 | — | — | US | disclosed |
| US-9453018-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F11 | BCHE 3143/4885CA1 3351/4885CA2 2795/4885 |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | BCHE 3025/4885CA1 3538/4885CA2 2831/4885 |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | BCHE 3025/4885CA1 3538/4885CA2 2831/4885 |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | BCHE 3143/4885CA1 3351/4885CA2 2795/4885 |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | BCHE 3025/4885CA1 3538/4885CA2 2831/4885 |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI2, F2, TFPI | BCHE 3492/4885CA1 3476/4885CA2 2355/4885 |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | BCHE 3025/4885CA1 3538/4885CA2 2831/4885 |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | TFPI, TFPI2, F2 | BCHE 3025/4885CA1 3538/4885CA2 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.